See All Slides - tctmd.com

Slides

Presentation THT 2023

Guideline Directed Medication Therapies (GDMT): Decreasing Time From Initiation to Core Therapy Use

Presenter: Nancy Albert

March 20, 2023

Presentation THT 2023

The Projected Burden of Heart Failure

Presenter: Joseph Rogers

March 20, 2023

Presentation THT 2023

Reprieve: Intelligent Diuretic Management Strategies

Presenter: Jeffrey Testani

March 20, 2023

Presentation THT 2023

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

Presenter: Mandeep Mehra

March 20, 2023

Presentation THT 2023

Aquapass: Using the Sweat Gland as a Nephron

Presenter: Doron Aronson

March 20, 2023

Presentation THT 2023

The Leaders of the Pack: Why Improving Investigator Diversity in Heart Failure Trials is a Key Priority

Presenter: Eldrin Lewis

March 20, 2023

Presentation THT 2023

Cardionomics: Tapping Into the Cardiac Plexus

Presenter: Sitaramesh Emani

March 20, 2023

Presentation THT 2023

Recruitment Strategies for Vulnerable and Marginalized Trial Participants

Presenter: Wayne Batchelor

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

Presentation THT 2023

Pullers: Devices That Reduce Renal Vein Pressure

Presenter: Navin Kapur

March 20, 2023

Advertisement

Slides

Guideline Directed Medication Therapies (GDMT): Decreasing Time From Initiation to Core Therapy Use

The Projected Burden of Heart Failure

Reprieve: Intelligent Diuretic Management Strategies

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

Aquapass: Using the Sweat Gland as a Nephron

The Leaders of the Pack: Why Improving Investigator Diversity in Heart Failure Trials is a Key Priority

Cardionomics: Tapping Into the Cardiac Plexus

Recruitment Strategies for Vulnerable and Marginalized Trial Participants

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Pullers: Devices That Reduce Renal Vein Pressure

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content